Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript
Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.
How this was made
The 30-second read
Why it matters
Q2 results show modest revenue growth and same-facility net revenue up 5%, but year-to-date adjusted EBITDA margin declined to 13.7% from 14.5%, reflecting payer mix effects. Management reaffirmed full-year guidance and indicated forward guidance will be updated upon closing of a pending transaction.
Market read
Traders can reassess near-term expectations for revenue growth versus margin trajectory based on same-facility KPIs and payer mix commentary, with guidance reaffirmation as the primary catalyst.
What to watch
The transcript mentions a pending Idaho Falls transaction and supplemental metrics posted for a pro forma mix, but the excerpt does not quantify transaction impact or updated forward guidance details.
Background
Surgery Partners is an ASC management company focused on short-stay surgical facilities, with growth via same-facility performance, de novo development, and selective M&A.
Ticker impact
Surgery Partners reported Q2 2026 net revenue of about $849M and adjusted EBITDA about $125M, reaffirming full-year guidance.
Near-term bias modestly positive if investors focus on same-facility growth and guidance reaffirmation, but tempered by year-to-date EBITDA margin decline.
The transcript provides concrete quarterly and year-to-date financials plus operating KPIs (same-facility revenue, cases, payer mix) and explicitly states guidance reaffirmation, which is actionable for positioning.
Market effects
ASC operators may see read-across from Surgery Partners' emphasis on higher-acuity mix and physician recruiting as key drivers of same-facility growth.
No specific regional demand shock is disclosed; payer mix shifts are described as isolated to larger surgical hospitals.
Limited, as the disclosure is company-specific and not tied to macro policy or cross-border events.
Counterpoint
The call highlights government payer mix rising and YTD adjusted EBITDA margin falling, which could signal cost or reimbursement headwinds despite revenue growth.
Key entities
- companySurgery Partners
Reported Q2 2026 financial and operating metrics, including same-facility revenue growth, payer mix shifts, and guidance reaffirmation.
- corporate_eventIdaho Falls transaction
Pending transaction described as an important step; management says forward guidance will be updated upon closing.
